The Japanese Journal of Pharmacology · 1997 · 19 citations · 11 references
MedicinePharmacologyClinical PharmacologyExperimental PharmacologyPharmacodynamicsMolecular Mechanisms Of ToxicityPharmacodynamics Of ImmunotherapiesLethal InjectionLipopolysaccharide-induced DamagePlasminogen ActivatorsProtective Treatments
We have examined the effects of an inhibitor of plasminogen activator inhibitor-1 (PAI-1) production, (3E,4E)-3-benzylidene-4-(3,4,5-trimethoxy-benzylidene)pyrrol idine-2,5-dione (T-686), on lipopolysaccharide (LPS)-induced death in mice. Oral administration of T-686 (10 and 100 mg/kg/day) for 8 days prior to the LPS injection (35 mg/kg, i.v.) protected mice from the lethal effect of LPS in a dose-dependent fashion. Moreover, treatment with 100 mg/kg T-686 attenuated the increase in plasma PAI-1 activity and the decrease in AT-III activity induced by LPS. We conclude that T-686 can reduce the mortality of mice induced by LPS, which seems to be partially correlated with both hypercoagulation and hypofibrinolysis.
11
Michael Sawdey, David J. Loskutoff · Journal of Clinical Investigation · 1991 · 411 citations · Full text